scholarly journals P081 Clinical Characteristics and Molecular Patterns Of RET-Rearranged Lung Cancer in Chinese Patients

2018 ◽  
Vol 13 (12) ◽  
pp. S1077
Author(s):  
S. Fei ◽  
K. Zhang ◽  
H. Chen ◽  
Y. Wang ◽  
L. Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Characteristics ◽  
Chinese Patients ◽  
Molecular Patterns

scholarly journals Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients

2019 ◽  
Vol 27 (5) ◽  
pp. 575-582 ◽  
Author(s):  
Kai Zhang ◽  
Huajun Chen ◽  
Ye Wang ◽  
Lin Yang ◽  
Chengzhi Zhou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Clinical Characteristics ◽  
Progression Free Survival ◽  
Chinese Patients ◽  
Lung Cancers ◽  
Lung Cancer Patients ◽  
Molecular Features ◽  
Molecular Patterns ◽  
Next Generation Sequencing Ngs

RET rearrangement has been proven as an oncogenic driver in patients with lung cancer. However, the prevalence, clinical characteristics, molecular features, and therapeutic options in RET-rearranged patients remain unclear, especially in Chinese lung cancer patients. We retrospectively collected 6,125 Chinese lung cancer patients who have been profiled using next-generation sequencing (NGS). The clinical demographics and molecular features of RET rearrangement-positive patients were analyzed. RET rearrangements were identified in 84 patients with a proportion of 1.4% in our cohort. The median age at diagnosis was 58 years, and it mainly occurred in females with adenocarcinoma histology. KIF5B-RET was the most frequent fusion type and accounted for 53.8% (57/106) of all RET fusions identified, with K15-R12 as the most frequent variant (71.9%). Among 47 RET+ patients profiled with larger panels, 72.3% (34/47) harbored concurrent alterations. TP53 ranked as the most common concurrent alteration, and concomitant EGFR oncogenic alterations were identified in seven patients. Moreover, an adenocarcinoma patient harboring concurrent RET fusion and EGFR L858R responded to combinatorial treatment of cabozantinib and osimertinib, with a progression-free survival of 5 months. Our study improved knowledge of clinical characteristics and molecular features of RET-rearranged lung cancers in China. It might be helpful to guide clinicians for more effective personalized diagnostic and therapeutic approaches.

Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients

2016 ◽  
Vol 12 (10) ◽  
pp. 1243-1249 ◽  
Author(s):  
Guangming Tian ◽  
Xinliang Zhao ◽  
Jun Nie ◽  
Ling Dai ◽  
Weiheng Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Characteristics ◽  
Small Cell ◽  
Chinese Patients ◽  
Small Cell Lung

scholarly journals Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Huaxia Yang ◽  
Yadong Wang ◽  
Ziqi Jia ◽  
Yanyu Wang ◽  
Xiaoying Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cell ◽  
T Cell Receptor ◽  
Clinical Characteristics ◽  
Cell Receptor ◽  
Shannon Index ◽  
Chinese Patients ◽  
Similarity Metrics ◽  
Tumor Escape ◽  
Tcr Repertoire

Lung cancer is the leading cause of cancer-related deaths worldwide, and its occurrence is related to the accumulation of gene mutations and immune escape of the tumor. Sequencing of the T-cell receptor (TCR) repertoire can reveal the immunosurveillance status of the tumor microenvironment, which is related to tumor escape and immunotherapy. This study aimed to determine the characteristics and clinical significance of the TCR repertoire in lung cancer. To comprehensively profile the TCR repertoire, results from high-throughput sequencing of samples from 93 Chinese patients with lung cancer were analyzed. We found that the TCR clonality of tissues was related to smoking, with higher clonality in patients who had quit smoking for less than 1 year. As expected, TCR clonality was correlated with stages: patients with stage IV disease showed higher clonality than others. The correlation between TCR repertoire and epidermal growth factor receptor (EGFR) status was also investigated. Patients with EGFR non-L858R mutations showed higher clonality and a lower Shannon index than other groups, including patients with EGFR L858R mutation and wild-type EGFR. Furthermore, we analyzed the TCR similarity metrics—that is, the TCR shared between postoperative peripheral blood and tissue of patients with non-distant metastasis of lung cancer. A similar trend was found, in which patients with EGFR L858R mutations had lower overlap index (OLI) and Morisita index (MOI) scores. Moreover, the OLI showed a positive correlation with several clinical characteristics, including the tumor mutational burden of tissues and the maximum somatic allele frequency of blood; OLI showed a negative correlation with the ratio of CD4+CD28+ in CD4+ cells and the ratio of CD8+CD28+ in CD8+ cells. In conclusion, TCR clonality and TCR similarity metrics correlated with clinical characteristics of patients with lung cancer. Differences in TCR clonality, Shannon index, and OLI across EGFR subtypes provide information to improve understanding about varied responses to immunotherapy in patients with different EGFR mutations.

Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer

2019 ◽  
Vol 20 (6) ◽  
pp. 405-411 ◽  
Author(s):  
Antonio Mazzella ◽  
Mauro Loi ◽  
Audrey Mansuet-Lupo ◽  
Antonio Bobbio ◽  
Helene Blons ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Characteristics ◽  
Adrenal Metastases ◽  
Molecular Phenotyping

scholarly journals P86.18 Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina.

2021 ◽  
Vol 16 (3) ◽  
pp. S680
Author(s):  
J. Blaquier ◽  
M. Cerini ◽  
V. Denninghoff ◽  
F. Jauk ◽  
V. Wainsztein ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Characteristics

scholarly journals Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yongliang Zhang ◽  
Yu Yao ◽  
Yaping Xu ◽  
Lifeng Li ◽  
Yan Gong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Chinese Patients ◽  
Plasma Samples ◽  
Small Cell Lung ◽  
Pan Cancer ◽  
Tumor Dna

AbstractCirculating tumor DNA (ctDNA) provides a noninvasive approach to elucidate a patient’s genomic landscape and actionable information. Here, we design a ctDNA-based study of over 10,000 pan-cancer Chinese patients. Using parallel sequencing between plasma and white blood cells, 14% of plasma cell-free DNA samples contain clonal hematopoiesis (CH) variants, for which detectability increases with age. After eliminating CH variants, ctDNA is detected in 73.5% of plasma samples, with small cell lung cancer (91.1%) and prostate cancer (87.9%) showing the highest detectability. The landscape of putative driver genes revealed by ctDNA profiling is similar to that in a tissue-based database (R2 = 0.87, p < 0.001) but also shows some discrepancies, such as higher EGFR (44.8% versus 25.2%) and lower KRAS (6.8% versus 27.2%) frequencies in non-small cell lung cancer, and a higher TP53 frequency in hepatocellular carcinoma (53.1% versus 28.6%). Up to 41.2% of plasma samples harbor drug-sensitive alterations. These findings may be helpful for identifying therapeutic targets and combined treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document